Journal of Clinical and Translational Endocrinology最新文献

{"title":"Utilizing near-peer teaching to expand obesity medicine training within an internal medicine residency curriculum","authors":"Ann Forrest ,&nbsp;Maria Gabriela Negron Marte ,&nbsp;Amanda George ,&nbsp;Li Liu ,&nbsp;Stéphanie B. Mayer","doi":"10.1016/j.jcte.2025.100411","DOIUrl":"10.1016/j.jcte.2025.100411","url":null,"abstract":"<div><h3>Objectives</h3><div>Obesity management is within the scope of an internist’s practice in the primary care setting; however, physicians feel unprepared to address the topic. Many internal medicine (IM) residency programs struggle to include obesity management in their curricula. The objective of our study is to assess the self-reported knowledge and comfort of IM residents when addressing overweight and obesity following a near-peer teaching session on the subject.</div></div><div><h3>Methods</h3><div>A near-peer teaching session on the topic of overweight and obesity was presented in morning report format for IM residents. Pre-session, immediate post-session, and three-month follow-up surveys were completed to compare comfort and self-reported knowledge on obesity management in relation to the session. Z-test was used to analyze answers between survey time points.</div></div><div><h3>Results</h3><div>Out of fifty-one eligible residents, forty-one residents attended the teaching session. Thirty-three residents responded to the pre-session survey, twenty-five to the immediate post-session survey, and eighteen to the three-month follow-up survey. At baseline, residents recognized obesity as a chronic medical condition and were willing to address the topic with patients. Between pre- and immediate post-session surveys, residents demonstrated increased self-reported knowledge in recognizing BMI cutoffs, criteria for bariatric surgery, comfort offering dietary advice, documentation of obesity as a diagnosis, awareness of obesity management tools including nutrition services and willingness to provide them to patients. At the three-month follow-up survey, there was retention of BMI cutoffs and nutrition service availability, but there were partial losses in self-reported knowledge of criteria for bariatric surgery and locating obesity management tools.</div></div><div><h3>Conclusions</h3><div>A near-peer led teaching session in a morning report style format can increase residents’ self-reported knowledge and comfort when addressing overweight and obesity, without overburdening the curriculum. Spaced review of the topic may overcome the partial knowledge losses seen in our IM resident population.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100411"},"PeriodicalIF":3.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144772476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cell division cycle 20 promotes tumor progression and predicts poor clinical outcome in childhood and adult adrenocortical carcinoma","authors":"Jiahong Chen ,&nbsp;Peisheng Huang ,&nbsp;Yongcheng Shi ,&nbsp;Shanshan Mo ,&nbsp;Cheng-Ya Hsu ,&nbsp;Shumin Fang ,&nbsp;Chuanfan Zhong ,&nbsp;Le Zhang ,&nbsp;Lanting Zuo ,&nbsp;Jianming Lu ,&nbsp;Weide Zhong ,&nbsp;Zhuoya Huang ,&nbsp;Zhong Dong","doi":"10.1016/j.jcte.2025.100406","DOIUrl":"10.1016/j.jcte.2025.100406","url":null,"abstract":"<div><h3>Background</h3><div>Adrenocortical carcinoma (ACC) is an uncommon and highly aggressive tumor with a grim prognosis. Numerous investigations have elucidated a close association between the dysregulated expression of multiple genes within tumors and the initiation as well as progression of neoplasms. These dysregulated genes not only exert pivotal roles in tumorigenesis but also harbor significant potential as prognostic biomarkers.</div></div><div><h3>Methods</h3><div>This study utilized transcriptomic data from public databases of ACC and normal tissue samples to screen for differentially expressed genes (DEGs). Subsequently, univariate Cox regression and receiver operating characteristic (ROC) curve were employed to identify potential prognostic biomarkers for ACC. Immunohistochemistry and in vitro cell experiments were conducted to validate the expression and potential functions of Cell division cycle 20 (CDC20) in ACC cells. Additionally, we analyzed the relationship between CDC20 and CD8+ T cells, immunotherapy response, somatic mutations, and copy number variations.</div></div><div><h3>Results</h3><div>CDC20 has emerged as an independent adverse prognostic factor in ACC, with significantly elevated expression levels. In vitro cell experiments have demonstrated that downregulation of CDC20 expression suppresses proliferation and migration of ACC cells. Notably, our study has identified CDC20 expression as most closely associated with TP53 mutation. Additionally, CDC20 expression levels exhibit a negative correlation with infiltration of CD8+ T cells. Patients with low CDC20 expression may show improved response to anti-PD-1 immunotherapy.</div></div><div><h3>Conclusion</h3><div>CDC20 serves as a reliable and robust biomarker in ACC, playing a crucial role in predicting survival outcomes and assessing immunotherapy response in adult and childhood ACC patients.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100406"},"PeriodicalIF":4.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144549894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SGLT2 inhibitor therapy in overweight and obese patients with cystic fibrosis-related diabetes: Case series","authors":"Ammar Ahmed ,&nbsp;Roshini Asirvatham ,&nbsp;Jagdeesh Ullal ,&nbsp;Amir Moheet","doi":"10.1016/j.jcte.2025.100403","DOIUrl":"10.1016/j.jcte.2025.100403","url":null,"abstract":"<div><div>Cystic fibrosis-related diabetes (CFRD) is the most prevalent extrapulmonary comorbidity in CF. While insulin remains the standard treatment, increasing rates of overweight and obesity due to CFTR modulators highlight the need for new therapies. SGLT2 inhibitors, effective in type 2 diabetes, have not been studied in CFRD. This case series presents eight CFRD patients treated with SGLT2 inhibitors alongside insulin for one year. Half had BMI reductions (1.33–2.89 kg/m2); others had increases. Glycemic control improved in six, worsened in two due to insulin nonadherence. Insulin adjustments showed no pattern. One patient discontinued due to genital infections; overall tolerance was high.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100403"},"PeriodicalIF":4.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144365262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term primary pharmacotherapy of giant prolactinomas: A comparison of different cabergoline dosages","authors":"Hána Václav Jr. ,&nbsp;Vaněčková Manuela ,&nbsp;Kršek Michal ,&nbsp;Krausová Adéla ,&nbsp;Ježková Jana ,&nbsp;Kosák Mikuláš ,&nbsp;Diblík Pavel ,&nbsp;Netuka David ,&nbsp;Masopust Václav ,&nbsp;Májovský Martin ,&nbsp;Liščák Roman ,&nbsp;Hána Václav","doi":"10.1016/j.jcte.2025.100418","DOIUrl":"10.1016/j.jcte.2025.100418","url":null,"abstract":"<div><h3>Objectives</h3><div>Dopamine agonists serve as first-line therapies for most giant prolactinomas. The objective of this study was to assess the differential impact of dopamine agonist dosing strategies on biochemical (prolactin normalisation) and radiological (tumour size reduction) responses in patients with giant prolactinomas.</div></div><div><h3>Design</h3><div>A single-centre retrospective real-life 23-year follow-up study.</div></div><div><h3>Methods</h3><div>Thirty-three patients with giant prolactinomas (≥ 4 cm) were treated with primary pharmacotherapy. We assessed pituitary function, the effect of therapy and different dosing regimens on prolactin normalisation and tumour size, the effect of surgery for complications and the effect of radiotherapy in resistant patients.</div></div><div><h3>Results</h3><div>Out of thirty-three consecutive patients (mean age 42 years), 27 were men, and 6 were women. The baseline mean prolactin concentration was 7506 µg/L. The treatment of choice was cabergoline in 30 patients, terguride in 2 patients, and bromocriptine in 1 patient. In patients receiving a high dose of cabergoline (3.5 mg weekly), we observed a faster normalisation of prolactin but not faster reduction in tumour size than in patients receiving a low dose (1–2.5 mg weekly). A total of 9/33 (27 %) patients underwent surgery for complications, 3 of whom were irradiated by Leksell gamma knife for partial resistance. In 4/33 patients we were able to stop pharmacotherapy after 10–20 years of treatment. The remaining 29/33 patients remained on pharmacological treatment.</div></div><div><h3>Conclusions</h3><div>Dopamine agonists are safe and only required treatment in 2/3 of patients treated with pharmacotherapy as a first-line treatment. Higher doses of cabergoline accelerate prolactin normalisation but do not confer additional benefit in early tumour shrinkage.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100418"},"PeriodicalIF":3.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144925081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationships of triglyceride–glucose index and body mass index with 5-year all-cause mortality in patients with diabetes and comorbid hypertension: Evidence from two prospective cohort studies","authors":"Yilu Liu ,&nbsp;Hongzhao You ,&nbsp;Yingxuan Zhu ,&nbsp;Fang Luo ,&nbsp;Yanyan Zhao ,&nbsp;Dingyue Zhang ,&nbsp;Ying Xiao ,&nbsp;Shijie You ,&nbsp;Rui Zhang ,&nbsp;Yingdong Han ,&nbsp;Jing Li ,&nbsp;Shouling Wu ,&nbsp;Jiansong Yuan ,&nbsp;Shuohua Chen ,&nbsp;Weixian Yang","doi":"10.1016/j.jcte.2025.100416","DOIUrl":"10.1016/j.jcte.2025.100416","url":null,"abstract":"<div><h3>Aims</h3><div>To characterize the complex relationships of body mass index (BMI) and triglyceride–glucose index (TyG) with 5-year all-cause mortality in patients with diabetes mellitus and comorbid hypertension.</div></div><div><h3>Methods</h3><div>Overall, 5,728 patients from the 1999–2014 US National Health and Nutrition Examination Survey (NHANES) cycles and 3,456 from the 2005–2010 China Kailuan cycles were included. TyG was calculated as the logarithmic product of the fasting triglyceride and glucose concentrations.</div></div><div><h3>Results</h3><div>The prevalence of 5-year all-cause mortality was 8.4 % in the NHANES population and 9.2 % in the Kailuan cohort. TyG mediated the association between BMI and all-cause mortality, being responsible for 38.4 % in the NHANES database and 41.6 % in the Kailuan cohort. Significant multiplicative effects were identified between TyG and BMI, which were closer for patients with high BMI. When stratified by BMI and TyG, high-risk subgroups were identified and had higher risks of all-cause mortality than the intermediate- and low-risk subgroups (both log-rank <em>P</em> &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>TyG mediated a considerable proportion of the effect of BMI on all-cause mortality in patients with diabetes and hypertension. The combination of BMI and TyG could be useful for the risk stratification of all-cause mortality. Measures aimed at weight loss might reduce the all-cause mortality risk associated with insulin resistance.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100416"},"PeriodicalIF":3.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144890585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationship between sarcopenic obesity and prediabetes in adolescents: Analysis of the national health and nutrition examination survey from 2011 to 2016","authors":"Gang Cheng ,&nbsp;Ying Zhou ,&nbsp;Yan Wang,&nbsp;Li Tao,&nbsp;Jianghong Xu","doi":"10.1016/j.jcte.2025.100414","DOIUrl":"10.1016/j.jcte.2025.100414","url":null,"abstract":"<div><h3>Objective</h3><div>The purpose of this study was to observe the relationship between sarcopenic obesity and prediabetes in adolescents. Methods: A cross-sectional retrospective study was conducted on United States adolescents aged 12–19 years. Data were extracted from the National Health and Nutrition Examination Survey (NHANES) 2011–2012, 2013–2014, and 2015–2016 cycles. Sarcopenic obesity was defined as waist circumference at or above the 90th percentile for age and sex and appendicular skeletal muscle mass divided by weight below the lower quintile for age and sex.</div></div><div><h3>Results</h3><div>The prevalence of prediabetes was 22.2 % in the normal group, 15.0 % in the sarcopenia alone group, 22.3 % in the obesity alone group, and 36.9 % in the sarcopenic obesity group. In univariate logistic regression, adolescents with sarcopenic obesity had a higher odds of prediabetes compared to the normal group (odds ratio = 2.048, 95 % CI: 1.125–3.728, <em>P</em> = 0.020). After adjusting for confounders, the odds remained significantly elevated (adjusted odds ratio = 2.060, 95 % CI: 1.178–3.604, <em>P</em> = 0.012).</div></div><div><h3>Conclusion</h3><div>The present study demonstrates that sarcopenic obesity was closely associated with an increased odds of prediabetes in United States adolescents.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100414"},"PeriodicalIF":3.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144879078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"False negative rate and concordance of ThyGeNEXT®+ThyraMIR® testing with post-thyroidectomy histopathology","authors":"Sobrina S. Mohammed ,&nbsp;Daniel Mettman ,&nbsp;Mariana Garcia-Touza ,&nbsp;Maricel Ridella ,&nbsp;Betty Drees","doi":"10.1016/j.jcte.2025.100396","DOIUrl":"10.1016/j.jcte.2025.100396","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to assess the false negative rate (FNR) and concordance of pre-operative ThyGeNEXT®+ThyraMIR® testing in Bethesda category III-V thyroid nodules by comparing results with post-surgical histopathology in thyroid cancer.</div></div><div><h3>Methods</h3><div>A retrospective review was conducted on 19 patients with Bethesda III-V thyroid nodules who underwent ThyGeNEXT®+ThyraMIR® testing followed by total thyroidectomy with histopathology confirming thyroid cancer. Fine needle aspiration (FNA) cytology, molecular test results, post-surgical histopathology and comprehensive genomic profiling reports (when available) were examined. Concordance was assessed by comparing pre-operative test results (mutations or malignant miRNA expression) to post-surgical histopathology. Discrepancies were further explored using Tempus xT genomic profiling for additional mutations and evaluation of tumor heterogeneity. The FNR was calculated accordingly.</div></div><div><h3>Results</h3><div>FNR was 10.5 % and there was a high positive concordance with 89.5 % of cases testing positive for mutations or malignant miRNA classifiers. TERT c.-146C&gt;T, NRAS Q61R, and BRAF V600E were among mutations identified. Comprehensive genomic profiling clarified false negatives, revealing insights into the impact of tumor heterogeneity. The miRNA classifier proved effective in detecting malignancy, in cases with subthreshold and RAS mutations or without common genetic alterations. Reliable results were obtained from diverse specimen types.</div></div><div><h3>Conclusions</h3><div>The low false-negative rate and positive concordance with histopathology highlights the utility of ThyGeNEXT® + ThyraMIR® in enhancing risk stratification and guiding personalized management of indeterminate thyroid nodules and thyroid cancer.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"40 ","pages":"Article 100396"},"PeriodicalIF":4.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143876906","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “False negative rate and concordance of ThyGeNEXT®+ThyraMIR® testing with post-thyroidectomy histopathology” [J. Clin. Translat. Endocrinol. 40 (2025) 100396]","authors":"Sobrina S. Mohammed ,&nbsp;Daniel Mettman ,&nbsp;Mariana Garcia-Touza ,&nbsp;Betty Drees ,&nbsp;Maricel Ridella","doi":"10.1016/j.jcte.2025.100397","DOIUrl":"10.1016/j.jcte.2025.100397","url":null,"abstract":"","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"40 ","pages":"Article 100397"},"PeriodicalIF":4.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144185076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Testicular function and fertility outcomes in males with CF: A multi center retrospective study of men with congenital bilateral absence of the vas deferens based on CFTR mutation status","authors":"Rossella Cannarella ,&nbsp;Danielle Velez Leitner ,&nbsp;Marissa Weiss ,&nbsp;Sarah C. Vij","doi":"10.1016/j.jcte.2025.100388","DOIUrl":"10.1016/j.jcte.2025.100388","url":null,"abstract":"<div><h3>Background</h3><div>Modern cystic fibrosis (CF) treatments, particularly CFTR modulators, have allowed males with CF (MwCF) to live longer, healthier lives and pursue parenthood. Approximately 98% of MwCF have congenital bilateral absence of the vas deferens (CBAVD). While research shows MwCF experience spermatogenic dysfunction alongside obstructive azoospermia, understanding male reproductive health in MwCF remains limited. This study retrospectively examines testicular function and intracytoplasmic sperm injection outcomes of the partners of males with CBAVD, stratified by CF mutation status (CF, CF carriers, no known mutation).</div></div><div><h3>Subjects and Methods</h3><div>This multicenter, retrospective study assessed sperm retrieval outcomes and testicular function in males with CBAVD. Participants were categorized into three groups: MwCF (Group 1), CFTR gene mutation carriers (CFTR carriers, Group 2), and CBAVD males without CFTR mutations (Group 3). We collected data on genetic testing, testicular hormone levels (FSH, LH, total testosterone), sperm retrieval methods, and reproductive outcomes. Statistical analysis was used to assess intergroup differences.</div></div><div><h3>Results</h3><div>Thirty subjects were included (Group 1: 14, Group 2: 11, Group 3: 5). No significant differences in demographic, anthropometric, or reproductive characteristics were found across groups. Hormone levels (LH, FSH, and testosterone) were similar among groups. In Group 1, 42 % had elevated FSH levels. The prevalence of hypogonadism was 16.7 % in Group 1. Group 3 had a significantly lower fertilization rate (p &lt; 0.01), but no differences were found in blastocyst formation, pregnancy, miscarriage, or live birth rates.</div></div><div><h3>Conclusions</h3><div>Our data support the presence of primary spermatogenic dysfunction in some MwCF. However, reproductive outcomes were similar across all groups.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"40 ","pages":"Article 100388"},"PeriodicalIF":4.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143735198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of GIP and GLP-1 infusion on bone resorption in glucose intolerant, pancreatic insufficient cystic fibrosis","authors":"Wang Shin Lei ,&nbsp;XianYan Chen ,&nbsp;Lingyu Zhao ,&nbsp;Tanicia Daley ,&nbsp;Bradley Phillips ,&nbsp;Michael R. Rickels ,&nbsp;Andrea Kelly ,&nbsp;Joseph M. Kindler","doi":"10.1016/j.jcte.2025.100392","DOIUrl":"10.1016/j.jcte.2025.100392","url":null,"abstract":"<div><h3>Context</h3><div>Diabetes and bone disease are common in cystic fibrosis (CF) and primarily occur alongside exocrine pancreatic insufficiency (PI). “Incretins,” glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1), augment insulin secretion and regulate bone metabolism. In CF, PI dampens the incretin response. Loss of the insulinotropic effect of GIP in CF was recently identified, but effects on bone are unknown.</div></div><div><h3>Objective</h3><div>Determine effects of incretins on bone resorption markers in adults with PI-CF.</div></div><div><h3>Design</h3><div>Secondary analysis of a mechanistic double-blinded randomized placebo-controlled crossover trial including adults ages 18–40 years with PI-CF (n = 25).</div></div><div><h3>Intervention</h3><div>Adults with PI-CF received either GIP (4 pmol/kg/min) or GLP-1 (1.5 pmol/kg/min) infusion, followed by double-blind randomization to either incretin or placebo infusion. Non-CF healthy controls received double-blind GIP (4 pmol/kg/min) or placebo. Serum C-terminal telopeptide (CTX), a bone resorption marker, was assessed during the infusion over 80 (GIP) or 60 (GLP-1) minutes.</div></div><div><h3>Main Outcome Measures</h3><div>CTX (mg/dL) concentrations.</div></div><div><h3>Results</h3><div>In PI-CF, CTX decreased during GIP infusion, but not during placebo (time-by-treatment interaction P &lt; 0.01). GLP-1 did not affect CTX. In non-CF healthy controls, time-by-treatment interaction was not significant (P = 0.23), but CTX decreased during GIP (P = 0.02) but not placebo (P = 0.47).</div></div><div><h3>Conclusions</h3><div>GIP evokes a bone anti-resorptive effect in people with PI-CF. Since the incretin response is perturbed in PI-CF, and an infusion of GIP lowers bone resorption, the “gut-bone axis” in CF-related bone disease requires attention.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"40 ","pages":"Article 100392"},"PeriodicalIF":4.2,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143825630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}